Switch Therapeutics is an emerging biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science, with the goal of treating a range of diseases – affecting the central nervous system and systemic indications – with significant unmet need. The CASi (Conditionally Activated siRNA) platform, the company’s novel gene knockdown approach, is based on technology developed by renowned researchers in the field of RNA and drug development from Caltech, Harvard Medical School and City of Hope. CASi combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity. 

Biotechnology

Research

Switch Therapeutics

Dee Datta

Brandi Simpson

Charles Allerson

Shilpi Mahajan

Anindya Bhattacharya

Maxine Nelson

Clara Tourino

Joonhee Han

Alex Embusch

Marina Kovaliov

Jane Li

Robert Duff

Don Button

Craig Blanchette

Michael Wolfe

The Biology Research Team at Switch Therapeutics is dedicated to advancing the CASi platform by conducting innovative research focused on RNA interference mechanisms and their application in treating central nervous system disorders. This team collaborates closely to design and optimize nucleic acid-based therapeutics, conduct in-vivo studies, and explore the mechanisms of action, all aimed at addressing significant unmet medical needs in various disease areas. Their combined expertise drives the development of cutting-edge solutions that leverage the potential of gene knockdown technology.

Biology Research Team

Leadership Team

Research Associates

Research and Development

��

Biology Research Team

About

Team members

Other teams at Switch Therapeutics

Leadership Team

Research Associates

Research and Development

��������

Biology Research Team

About

Team members

Other teams at Switch Therapeutics

Leadership Team

Research Associates

Research and Development

��